Caffeine Treatment for Apnea of Prematurity and the Influence on Dose-Dependent Postnatal Weight Gain Observed Over 15 Years

Roy K. Philip, FRCPI, FRCPCH, FJFICMI, MD, MBA,1,2 Abu Ismail, MRCPI, MRCPS, DCH,1 Bernadette Murphy, MSc, MPSI,3 Adnan Mirza, MRCPCH, DCH, FRCPI,1 Collette Quinn, C-NEO,4 and Margo Dunworth, C-NEO4

Background and Aim: To analyze the influence on weight gain of infants exposed to two dosage regimens of oral caffeine citrate (CC) for apnea of prematurity.

Methods: Retrospective descriptive observational study of an eligible very low birth weight cohort over a 15-year period in an Irish University hospital. Data were analyzed between two distinct postnatal ages: 14–28 and 29–56 days.

Results: During the 15-year study, 457 infants were prescribed caffeine. Among the 14–28-day group, after applying exclusion criteria, 418 infants qualified. Two hundred forty-eight infants received 5 mg/(kg·day) and 170 received 10 mg/(kg·day) of CC. Among the 29–56-day group, 362 infants were identified and after applying exclusions, 332 fulfilled entry criteria [214 on 5 mg/(kg·day) and 118 on 10 mg/(kg·day) regimens]. Baseline characteristics of infants were comparable between groups without statistically significant differences. Mean daily weight gain (MDWG) in grams from day 14 to 28 showed a higher rate of increase for the 5 mg/(kg·day) group compared with the 10 mg/(kg·day) group (17.2 ± 12 g vs. 13.0 ± 10.2 g [p = 0.04]). From day 29 to 56, also MDWG was higher among infants on 5 mg/(kg·day) of CC compared with 10 mg/(kg·day) group (15.6 ± 10.8 g vs. 10.2 ± 9.8 g [p = 0.011]).

Conclusion: While a variety of measures are optimized to promote postnatal weight gain of premature infants close to an ideal intrauterine growth curve, not paying sufficient attention to one of the most widely used catabolic agents in neonatology is questionable and warrants vigilance. Additional nutritional measures could be offered to those with prolonged caffeine exposure.

Keywords: neonatal intensive care unit, caffeine citrate, apnea of prematurity, very low birth weight infants, methylxanthines, neonatal nutrition

Introduction

Apnea of prematurity (AOP) is defined as the cessation of spontaneous breathing by a premature infant lasting for more than 20 seconds and/or accompanied by hypoxia or bradycardia. Caffeine citrate (CC) is the commonest methylxanthine universally used in the management of AOP, which occurs in about 85% of infants born at less than 34 weeks of gestation. It has been the mainstay of pharmacologic treatment of apnea of AOP for over 30 years and is often prescribed for very premature infants until they reach a postmenstrual age of 32–34 weeks. Caffeine therapy for AOP has also been shown to reduce the rate of bronchopulmonary dysplasia and improves the rate of survival of very low birth weight (VLBW) infants without neurodevelopmental disability at 18–21 months. Caffeine is one of the most prescribed drugs in the current neonatal practice. Its efficacy,
tolerability, wide therapeutic index, and safety margin have made it the drug of choice for AOP and is often used cumulatively for many weeks with potential catabolic effects that could impact on the initial weight gain of this vulnerable population.7

Effects of caffeine intake during pregnancy were analyzed by the CARE Study Group and highlighted the association of fetal growth restriction to caffeine consumption during pregnancy.8 Their observation, along with similar findings from previous studies, suggests that fetal growth restriction secondary to high-dose maternal caffeine exposure is consistent across all trimesters.8,9 An incremental intake of caffeine during pregnancy was reported with LBW in 7% and small for gestational age (SGA) in 10%.10 Even though 18–21-month follow-up of caffeine-exposed infants for the treatment of AOP did not show reduction in weight or head circumference, somatic effect of dose- and duration-specific exposure during the neonatal period is not ascertained.

Caffeine readily crosses the blood/brain barrier and is a central nervous system stimulant. The principal mode of action is as an antagonist of adenosine receptors, which are G protein-coupled receptors.11,12 Caffeine is a competitive inhibitor of cAMP-phosphodiesterase enzyme, which converts cyclic AMP to its noncyclic form, thus allowing cAMP to build up in cells. Cyclic AMP participates in the activation of protein kinase A to begin the phosphorylation of specific enzymes used in the glucose synthesis. By blocking its removal, caffeine intensifies and prolongs the effects of epinephrine and epinephrine-like drugs.11,12 Cyclic AMP also directly increases heart rate, and caffeine increases the metabolic rate and oxygen consumption.14 Methylxanthines increase energy expenditure independently of physical activity and also enhance carbohydrate utilization in the infant.9 Studies have suggested that caffeine also reduced splanchnic blood flow in the neonatal gut.15 Caffeine is a diuretic and is based on the differential expression of adenosine A1 receptors. Caffeine increases glomerular filtration (causing diuresis) through action on afferent arteriole and reduces sodium reabsorption (causing natriuresis) at the level of proximal tubules.16–18 In baboon models with prematurity and respiratory distress, caffeine was associated with a doubling of urine output.19 The abovementioned mechanisms of action cumulatively contribute to the catabolic effects of caffeine during the neonatal period and thus negatively influence the weight gain.

While caffeine has respiratory benefits for preterm infants, it may have adverse molecular and cellular effects on the developing brain.20,21 Half-life of caffeine varies widely among infants based on their liver function status, exposure to certain concurrent medications, and the level of hepatic enzymes needed for metabolism. Among healthy adults, caffeine’s half-life is ~4.9 hours and in pregnant women 9–11 hours.8 Among infants and children, half-life is longer and for newborn infants could be up to 30 hours and as per a more recent study, the mean caffeine half-life was 87 ± 25 hours at 35 ± 1 week postmenstrual age.22

Caffeine is metabolized in the liver by the cytochrome P450 oxidase enzyme system (specifically the 1A2 isozyme) into three forms of dimethylxanthines, each with their own effects on the human body: (1) paraxanthine, (2) Theobromine, and (3) theophylline. They are further metabolized and excreted in urine.11 Paraxanthine increases lipolysis, which releases glycerol and fatty acids into blood to be used as fuel by the muscles. Theobromine is a vasodilator that increases the amount of nutrient flow to the brain and muscles. Theophylline acts as a smooth muscle relaxant, however, acts also as a chronotrope and inotrope, increasing heart rate and contractility.13

Caffeine through its effect on metabolic rate, diuretic action, hyperglycemic property, and catabolic tendency could influence the short-term growth, especially considering the current practice of prolonged postnatal caffeine therapy for AOP.8,10,23 A recent study has suggested an osteopenic effect of caffeine on premature infants and perhaps contributes adversely to the bone growth of extremely low birth weight (ELBW) population as well.24 We undertook this retrospective descriptive cohort study with an objective to determine the effects on mean daily weight gain (MDWG) of ELBW and VLBW infants treated with two different oral dosage schedules of CC for the treatment of AOP [5 mg/(kg·day) vs. 10 mg/(kg·day)].

Aims

To recognize and analyze the influence on postnatal weight gain of ELBW (below 1000 g birth weight) and VLBW (below 1500 g birth weight) infants exposed to two dosage regimens of oral CC for the management of AOP. To highlight the importance of growth monitoring and nutritional supplementation of premature infants exposed to prolonged duration of oral CC during a vulnerable period of critical somatic growth.

Methods

Patient population

This study was carried out in the NICU of University Maternity Hospital Limerick (UMHL), Ireland, between January 2002 and December 2016. Our maternity hospital has an in-birth rate approximating 5000 per year from a fairly fixed Caucasian population (ethnic minorities accounting for <10% of antenatal booking) with an antenatal steroid uptake of 91% for the eligible population. Our expressed breast milk exposure (mother’s own milk or donor breast milk) for the VLBW infants was 40% in 2005, 80% in 2012, and 91% in 2016. For the ELBW infants, breast milk use steadily increased from 20% in 2005, 80% in 2012, and 91% in 2016. For the ELBW infants, breast milk use steadily increased from 20% in 2005 to 90% in 2012 and through a quality improvement project reached 100% from 2014 to 2016.21 Inclusion criteria were (1) ELBW and VLBW infants born in our
hospital during the study period with birth weight of <1500 g and gestational age of 23–30 weeks, and (2) infants requiring treatment with oral CC for AOP. Exclusion criteria were (1) infants born with major congenital anomalies, (2) infants concurrently receiving other medications that could influence weight gain such as diuretics, ibuprofen, indomethacin, or postnatal corticosteroids, (3) infants transferred in/out of the unit from/to other neonatal centers, (4) infants with blood culture-proven sepsis during the course of oral caffeine treatment, (5) grade 3/4 intraventricular hemorrhage (IVH), (6) infants on fluid restriction, (7) infants who have received middle of the dosage range of CC from the treating team, (8) infants with necrotizing enterocolitis (NEC) with modified Bell’s stage 2b and above, and (9) infants while receiving intravenous caffeine. With our unit’s enhanced breast milk uptake for the prevention of NEC, there was a significant reduction of confirmed NEC in the second half of the study period (12 in 2002–2008 and 4 in 2009–2016 period). Intravenous caffeine was the choice for the first few days and was converted to oral route subsequently when tolerating sufficient nasogastric feeds. Infants who were initially on intravenous CC and subsequently converted to oral caffeine were included in the study. Those who did not initially receive intravenous caffeine, however, subsequently required oral caffeine during days 14–28 or 29–56 days, were also included in the study.

We did not exclude infants based on maternal caffeine/tobacco exposure and no data were collected in this regard. Infants were not excluded based on enteral versus parenteral route of nutrition, type of enteral feeding, or caloric/protein concentration of the feeds used. During the study period, powdered cow’s milk-based milk fortifier was used when infants reached 100 mL/kg of breast milk intake. We acknowledge that the use of breast milk fortifier or the universal use of donor breast milk was not established in our unit during the 2002–2010 period. Contribution by SGA within the study population was not separately analyzed.

Data sources

Study variables were obtained from the manually entered neonatal drug kardex (drug prescription charts), serially recorded weight chart from the nursing notes, demographic characteristics collected from the patient admission record in NICU, annually collated and submitted data toward the VON (Vermont Oxford Network) international benchmarking of all infants below 1500 g birth weight, hospital inpatient enquiry data, and the computerized patient admission system.

Intervention and outcome measurement

Infants during the study period were treated with two different dosing regimens: (1) 5 mg/(kg·day) dose of CC equivalent to 2.5 mg/(kg·day) caffeine base and (2) 10 mg/(kg·day) dose of CC equivalent to 5 mg/(kg·day) caffeine base. This resulted from the local guidelines based on published dosage schedules that recommended 5–10 mg/(kg·day) of CC as the maintenance dose after the initial loading of 20 mg/kg.5,6,10 The decisions on dose and duration of treatment were made entirely by the neonatal teams responsible for the care of the infants. There were no significant changes in our senior medical faculty during the study period. Our unit used oral CC 50 mg/5 mL (equivalent to caffeine base of 25 mg/5 mL), ML number 0427-01, Rosemount Pharmaceuticals Ltd. (Leeds, United Kingdom), during the first half of study and a specifically licensed product for neonatal use (Peyona®, CC 20 mg/mL oral solution by Chiesi Ltd.) during the second half.

Weight gain/loss in all infants admitted to the neonatal unit, including those enrolled in our study, was routinely measured three times weekly from birth to discharge by experienced neonatal nursing staff. More frequent weight checks were done if clinically indicated. For the purposes of this study, MDWG in g/(kg·day) was calculated for eligible infants between two specific time periods: (1) day of life 14–28 and (2) day of life 29–56. We chose to collect data on recorded MDWG only from day 14 of life, as many of the ELBW and VLBW infants often physiologically lose weight during the first week after birth (mean weight loss of 14% in the first 6 days) and often start regaining weight only from the second week of postnatal life.26 Analysis of other adverse effects of caffeine therapy or measuring serum levels of caffeine was not conducted as part of our study.27

Outcome analysis

For purposes of analysis, we also recorded the patient characteristics—gestation at birth, birth weight, duration and mode of ventilatory support, duration and dose of supplemental oxygen, and the kcal/kg of caloric nutritional intake and g/kg of nutritional protein intake (via enteral or parenteral nutrition). We tabulated our results using Microsoft Excel and statistical analysis was done with SPSS version 23 (SPSS®, Chicago, IL).

Ethical consideration

Study was approved by the University Maternity Hospital Audit Committee. Standard sets of clinical data from infants were included in our study, were collected anonymously, and infants were not exposed to placebo, novel intervention, or new dosage regimen.

Results

Study infants

During the 15-year study period, a total of 457 ELBW and VLBW infants were exposed to CC. Among the 14–28-day group, after applying the exclusion criteria,
418 qualified for the analysis. Among them, 248 received 5 mg/(kg·day) and 170 received 10 mg/(kg·day) of CC. Among the 29–56-day group, a total of 362 infants were identified and after applying the exclusions, 332 patients who fulfilled the entry criteria were included [214 on the 5 mg/(kg·day) of CC regimen and 118 on the 10 mg/(kg·day) regimen]. Baseline characteristics of these infants are summarized in Table 1 and are comparable without statistically significant differences. Table 2 summarizes the neonatal population characteristics over 15 years.

**Mean daily weight gain**

When MDWG was calculated for the study population from day of life 14 to 28, we found a higher rate of increase for the 5 mg/(kg·day) group compared with the 10 mg/(kg·day) group (17.2±12 vs. 13.0±10.2 [p=0.04]). A similar MDWG pattern was observed for the study population from day of life 29 to 56 as well. The rate of increase in MDWG was higher in the infants on the lower dose/kg of CC, that is, the 5 mg/(kg·day) cohort compared with the 10 mg/(kg·day) cohort (15.6±10.8 vs. 10.2±9.8 [p=0.011]). Our findings are summarized in Table 3.

Our unit only had a relatively small number of infants in the gestation and birth weight category who did not receive CC treatment during their NICU stay. This perhaps reflects a possible nonrestricted caffeine use in our unit or could be a manifestation of comfort of modern neonatal units to have a relatively liberal caffeine commencement and maintenance policy. Our VLBW and ELBW infants who were never exposed to postnatal caffeine were 157 and after using the exclusion criteria, only 92 infants qualified and 75 (81.5%) were ‡1000 g and ‡30 weeks of gestation at birth. Considering the limited number of infants in this subgroup, further analysis was not done as the derivation of clinical significance from our findings might not be prudent.

### Table 1. Baseline Characteristics of Premature Infants Exposed to Caffeine Citrate at Two Different Doses

| Days of treatment | 14–28 days | p | 29–56 days | p |
|-------------------|------------|---|------------|---|
| Dose of CC, mg/(kg·day) | 5 | 10 | 5 | 10 |
| n | 248 | 170 | 214 | 118 |
| Birth weight, g | 1074±418 | 1002±426 | 0.318 | 998±480 | 1010±442 | 0.229 |
| SIMV/PTV/HFOV, days | 24±18 | 22±14 | 0.476 | 20±17 | 22±14 | 0.440 |
| NCPAP/HFT, days | 28±16 | 32±12 | 0.270 | 30±18 | 34±14 | 0.440 |
| Kcal/kg | 116±18 | 120±26 | 0.158 | 118±22 | 122±24 | 0.153 |
| Supplemental oxygen, days | 22±12 | 18±10 | 0.157 | 38±20 | 36±13 | 0.610 |

Variables are given as mean±standard deviation.

CC, caffeine citrate; HFOV, high-frequency oscillatory ventilation; HFT, high-flow humidified oxygen therapy; NCPAP, nasal continuous positive airway pressure; PTV, patient-triggered ventilation; SIMV, synchronized intermittent mandatory ventilation.

### Table 2. Perinatal and Neonatal Population Characteristics Over 15 Years and the Trend in the Use of Caffeine Citrate Among Extremely Low Birth Weight and Very Low Birth Weight Infants

| Year | Number of ELBW and VLBW infants exposed to caffeine/year | Live births | Neonatal admissions | <1000 g | 1000–1500 g | Still births |
|------|---------------------------------------------------------|-------------|---------------------|--------|-------------|-------------|
| 2002 | 19                                                      | 4371        | 757                 | 6      | 25          | 26          |
| 2003 | 31                                                      | 4514        | 693                 | 16     | 26          | 28          |
| 2004 | 30                                                      | 4418        | 723                 | 20     | 17          | 27          |
| 2005 | 29                                                      | 4411        | 688                 | 10     | 31          | 28          |
| 2006 | 36                                                      | 4692        | 891                 | 16     | 31          | 16          |
| 2007 | 34                                                      | 5153        | 893                 | 12     | 43          | 22          |
| 2008 | 28                                                      | 5443        | 995                 | 12     | 26          | 30          |
| 2009 | 36                                                      | 5432        | 1087                | 13     | 31          | 24          |
| 2010 | 38                                                      | 5233        | 929                 | 17     | 35          | 32          |
| 2011 | 22                                                      | 5137        | 983                 | 11     | 16          | 23          |
| 2012 | 34                                                      | 4905        | 906                 | 17     | 26          | 22          |
| 2013 | 30                                                      | 4594        | 758                 | 13     | 29          | 18          |
| 2014 | 29                                                      | 4522        | 662                 | 13     | 23          | 17          |
| 2015 | 33                                                      | 4690        | 761                 | 12     | 33          | 24          |
| 2016 | 28                                                      | 4473        | 857                 | 10     | 24          | 16          |
| Total | 457                                                     | 71,988      | 12,583              | 198    | 416         | 353         |

University Maternity Hospital Limerick (UMHL), Ireland 2002–2016.

ELBW, extremely low birth weight; VLBW, very low birth weight.
to 21 specific side effects.10 Above observations suggest of CC among premature infants was noted to produce up to 30% more and was maintained at a higher mg/(kg-day) dose than at any other stage in life. A maintenance dose of CC was administered to a much higher mg/(kg-day) dose, especially those with chronic lung disease (CLD).

Current dosage regimens expose a 25–32-week gestation premature infant to a much higher mg/(kg-day) dose than at any other stage in life. A maintenance dose of 5–10 mg/(kg-day) of CC, often prescribed to 500–1500 g neonates (equivalent to 150–300 mg/day derived from tea/coffee for a 60 kg woman during second trimester of pregnancy, assuming comparable pharmacokinetics), is higher than the high level of exposure from dietary caffeine sources during pregnancy quoted in the CARE study and other recent observations.8,33 As per a recent systematic review of antenatal caffeine and impact on suboptimal fetal weight gain, existence of a dose–response relationship is suggestive of causation and there is no indication of a threshold effect.34 Caffeine with its psychoactive properties influences the sleep cycles and the somatic effects of this property also could modify the weight gain.35 Caffeine typically produces prolonged sleep latency, reduces the total sleep time, and worsens the sleep quality.35

A few observations from our study with the data spanned over a 15-year period are worth clarifying. The average weight gain in the younger group (days 14–26) is higher (Table 1) than the group (days 28–56) that is older and expected to be generally gaining more weight. Following clarifications could explain our observed findings: (1) many infants during 14–28 days were still in receipt of total parenteral nutrition or partial parenteral nutrition thus optimizing their nutritional requirement and resultant better weight gain, (2) during the first half of study period, our use of breast milk fortified was suboptimal, thus affecting the weight gain more among the 29–56 days compared with 14–28 days. As an unexpected observation, our ventilation days (nasal and tracheal combined) are very similar between the two groups (Table 1). We believe that the following could be the contributing factors: (1) The ELBW subgroup had a relatively longer intubation and ventilation and over 28 weeks of gestation was mainly on noninvasive support, (2) as the cohort is over a 15-year period, significant changes in ventilation management and the resultant variations in the duration of mechanical support, (3) those infants included from the first half of the study period perhaps had longer invasive ventilation, (4) contribution by outliers in the 29–56-day group—especially those with chronic lung disease (CLD).

The relative safety of caffeine compared with other drugs used in the treatment of AOP perhaps makes clinicians less vigilant to limit the duration of treatment of CC, thus leading to unnecessary prolonged exposure with possible side effects.32 Recent advances in respiratory support such as nasal continuous positive pressure with facilities for back-up breath/synchronization, nasal intermittent positive pressure ventilation with additional synchronization, as well as the nasal high-flow humidified oxygen therapy or low-flow systems, all need to be explored further along with postural adjustments and/or changes to infant care procedures, to avoid undue reliance on neonatal caffeine use. It is reassuring to read, from their 11-year follow-up by Schmidt et al.,
that caffeine therapy for AOP did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment.36 As per the current evidence, caffeine has a definite role in the management of AOP and perhaps in the reduction of CLD, however, may not be to the extent with which we use it liberally in the current neonatal practice.37 Seventy years ago, intramuscular Brandy 0.5 cc was used in newborn infants who failed to breathe, perhaps our stimulant pharmacotherapy to manage AOP of ELBW infants could 1 day be viewed with a similar surprise and dismay.

Audit process recommendations

Based on our observations, we have submitted recommendations to the neonatal clinical guideline development group to consider the lower dose of CC at 5 mg/kg (elemental caffeine of 2.5 mg/kg) as the standard starting maintenance dose and to appropriately incorporate additional nutritional input or consideration if ELBW and VLBW infants are maintained on a relatively higher dose of caffeine for prolonged periods.39 A reaudit is recommended for the audit cycle completion in 2019.

Limitations

We acknowledge the following limitations: (1) this is a retrospective descriptive observational study and not a randomized trial to make definitive conclusions on causality, (2) treating teams had the freedom to choose the caffeine dose as 2.5 or 5 mg/kg of elemental caffeine, (3) there is a possibility that treating clinicians might have chosen the higher dose for the “sicker” babies or in whom they have noted persistence of apnea or low caffeine levels on blood tests, (4) even though both groups were exposed to similar feeding regimens, fortifications, and had comparable breast milk uptake, there was no specific monitoring of the calorie or protein intake of the two groups, (5) over the 15-year period of data collection, there were evidence-based changes to various neonatal guidelines and policies that could have a bearing on the weight gain of infants, however, it is unlikely that such confounders only affected one group over the other, (6) we have not done a multiple logistic regression for the statistical analysis, (7) our mean MDWG calculation was derived from thrice-weekly weight checks rather than daily weight measurements; however, this was reflected across both patient groups, (8) two different CC preparations were used between the first and second halves of the study period, however, previous studies reported comparable clinical effects from both preparations,22 (9) observed weight trends were not correlated with the serum concentration of caffeine in the two groups, and (10) we excluded the initial postnatal days when infants were on intravenous caffeine and possibly had a relatively higher physiological weight loss. Combining enteral and parenteral routes of CC in the two study groups would have pharmacokinetic implications. By excluding infants during the parenteral caffeine use, perhaps we indirectly selected infants who are relatively stable in the “growing phase” in both groups thus adding more clinical relevance to our observations.

Conclusion

While a variety of dietary, ventilatory, and thermoregulatory measures are being optimized to augment postnatal weight gain close to the ideal intrauterine growth curves of ELBW and VLBW infants, not paying sufficient attention to one of the important catabolic agents widely used in the neonatal units around the world is questionable and warrants vigilance from the clinical neonatal community. Additional nutritional supplementation while on caffeine, especially at a higher dosage spectrum, is advisable to be incorporated to the feeding guidelines of units using CC for prolonged periods for the management of AOP. Our observation is neither powered nor randomized to establish causation, however; the observed association along with the supporting antenatal reports suggests the need for further studies to address this underperceived element of suboptimal postnatal weight gain among premature infants exposed to prolonged caffeine intake.

Compliance with Ethical Statements

Informed consent

Not applicable. Anonymous data source access was authorized after University Maternity Hospital Audit Committee approval.

Acknowledgments

Audit process guidance and quality improvement project (QIP) advice by Ms. Louise Reid, Audit Officer of UMHL, are acknowledged. Appreciation to BMJ rapid response for online acceptance of our response to CARE study group antenatal caffeine exposure in 2008. Contribution by neonatal nursing, midwifery, and medical teams who supported the project over a prolonged period is gracefully acknowledged. No funding support in the data collection, analysis, or preparation of the article.

Authors’ Contributions

R.K.P. recognized the significance of the theme, designed and supervised the study, developed the first draft, and edited the article. A.I. and A.M. collected the patient outcome data and compiled the clinical and demographic variables from the various data sources. M.D. collated the supporting information on ELBW and VLBW population. C.Q. tabulated the clinical characteristics of VLBW and ELBW infants as per the VON submission guidelines. B.M. extracted the prescription
details of caffeine, dosage regimens, and nutritional intake from neonatal drug prescriptions and edited the pharmacological section. R.K.P. collected and tabulated the perinatal and neonatal population details for the hospital. All authors critically revised the article for important academic content, agreed on the final draft, and approved its submission for publication.

Author Disclosure Statement

No competing financial interests exist.

References

1. Finer NN, Higgins R, Kattwinkel J, Martin RJ. Summary proceedings from the apnea-of-prematurity group. Pediatrics. 2006;117(Pt 2):S47–S51.
2. Barrington K, Fine N. The natural history of the appearance of apnea of prematurity. Pediatr Res. 1991;29:372–375.
3. Martin RJ, Abu-Shaweesh JM, Baird TM. Apnoea of prematurity. Paediatr Respir Rev. 2004;5(Suppl A):S377–S382.
4. Eichenwald EC, Aima A, Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics. 1997;100:354–359.
5. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357:1893–1902.
6. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354:2112–2121.
7. Shrestha B, Jawa G. Caffeine citrate—is it a silver bullet dependent biotransformation reactions. Biomed Biochim Acta. 1985;44:1189–1199.
8. List et al. The real-world routine use of caffeine citrate in preterm infants: A European Postauthorization Safety Study. Neonatology. 2016;109:221–227.
9. Ortweiler W, Simon HU, Splinter FK, Peiker G, Siegert C, Traeger A. Determination of caffeine and metamizole elimination in pregnancy and after delivery as an in vivo method for characterization of various cytochrome p-450 dependent biotransformation reactions. Biomed Biochim Acta. 1985;44:1189–1199.
10. Bolton S, Null G. Caffeine: Psychological effects, use and abuse. Orthomol Psychiatry. 1981;10:202–211.
11. Fisone G, Borgkvist A, Usiello A. Caffeine as a psycho-motor stimulant: Mechanism of action. Cell Mol Life Sci. 2004;61:857–872.
12. Stevenson DK. On the caffeinein of prematurity. N Eng J Med. 2007;357:1967–1968.
13. Lane AJP, Coombs RC, Evans DH, Levin RJ. Effect of caffeine on neonatal splanchic blood flow. Arch Dis Child Fetal Neonatal Ed. 1999;80:F128–F129.
14. Spindel E. Action of the methylxanthines on the pituitary and pituitary-dependent hormones. Prog Clin Biol Res. 1984;158:355–363.
15. Fenton RA, Poulsen SB, de la Mora Chavez S, et al. Caffeine-induced diuresis and natriuresis is independent of renal tubular NHE3. Am J Physiol Renal Physiol. 2015;308:F1409–F1420.
16. Williams M, Jarvis MF. Adenosine antagonists as potential therapeutic agents. Pharmacol Biochem Behav. 1988;29:433–441.
17. Yoder B, Thomson M, Coalson J. Lung function in immature baboons with respiratory distress syndrome receiving caffeine therapy: A pilot study. Acta Paediatr. 2005;94:92–98.
18. Atik A, Harding R, De Matteo R, et al. Caffeine for apnoea of prematurity: Effect on the developing brain. Neurotoxicology. 2017;58:94–102.
19. Bailey J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics. 2001;107:660–663.
20. Ali E, Rockman-Greenberg C, Moffatt M, Harvey J, Reed M, Jiang D. Caffeine is a risk factor for osteopenia of prematurity in preterm infants: A cohort study. BMC Pediatr. 2018;18:9.
21. Doyle J, Davidson D, Katz S, Varela M, Demeglio D, DeCristofaro J. Apnea of prematurity and caffeine pharmacokinetics: Potential impact on hospital discharge. J Perinatol. 2016;36:141–144.
22. Faramarzi F, Shiran M, Rafati M, Farhadi R, Salehifar E, et al. Determination of caffeine citrate in preterm infants: A randomized controlled trial. Eur J Pediatr. 2015;174:949–956.
23. Borszewska-Komacka MK, Hozejowski R, Rutkowska K. Caffeine for apnoea of prematurity: A systematic review and dose-response meta-analysis. PLoS One. 2017;12:e0189152.
24. Ambroziak F, Shimani M, Rafati M, Farhadi R, Salehifar E, et al. Caffeine for apnoea of prematurity: Effect on the developing brain. Neurotoxicology. 2017;58:94–102.
25. Bailey J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics. 2001;107:660–663.
26. Ali E, Rockman-Greenberg C, Moffatt M, Harvey J, Reed M, Jiang D. Caffeine is a risk factor for osteopenia in preterm infants: A cohort study. BMC Pediatr. 2018;18:9.
27. Doyle J, Davidson D, Katz S, Varela M, Demeglio D, DeCristofaro J. Apnea of prematurity and caffeine pharmacokinetics: Potential impact on hospital discharge. J Perinatol. 2016;36:141–144.
28. Faramarzi F, Shiran M, Rafati M, Farhadi R, Salehifar E, et al. Determination of caffeine citrate in preterm infants: A randomized controlled trial. Eur J Pediatr. 2015;174:949–956.
29. Borszewska-Komacka MK, Hozejowski R, Rutkowska K. Caffeine for apnoea of prematurity: A systematic review and dose-response meta-analysis. PLoS One. 2017;12:e0189152.
30. Ambroziak F, Shimani M, Rafati M, Farhadi R, Salehifar E, et al. Caffeine for apnoea of prematurity: Effect on the developing brain. Neurotoxicology. 2017;58:94–102.
31. Bailey J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics. 2001;107:660–663.
32. Ali E, Rockman-Greenberg C, Moffatt M, Harvey J, Reed M, Jiang D. Caffeine is a risk factor for osteopenia in preterm infants: A cohort study. BMC Pediatr. 2018;18:9.
33. Doyle J, Davidson D, Katz S, Varela M, Demeglio D, DeCristofaro J. Apnea of prematurity and caffeine pharmacokinetics: Potential impact on hospital discharge. J Perinatol. 2016;36:141–144.
34. James JE. Review: Higher caffeine intake during pregnancy increases risk of low birth weight. Evid Based Nurs. 2015;18:111.
35. Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep Med Rev. 2017;31:70–78.
36. Schmidt B, Roberts RS, Anderson PJ, et al. Caffeine for Apnea for Prematurity (CAP) Trial Group. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: An 11-year follow up of the CAP randomized clinical trial. JAMA Pediatr. 2017;171:564–572.
37. Kua LP, Lee SW. Systematic review and meta-analysis of clinical outcomes of early caffeine therapy in preterm neonates. Br J Clin Pharmacol. 2017;83:180–191.
38. Collis WRF. Modern Methods of Infant Management. London: William Heinemann Medical Books, Ltd.; 1948: pp.158–159.
39. Newkirk M, Shakeel F, Parimi P, et al. Comparison of calorie and protein intake of very low birth weight infants receiving mother’s own milk or donor milk when the nutrient composition of human milk is measured with a breast milk analyzer. Nutr Clin Pract. 2018. [Epub ahead of print]; DOI: 10.1002/ncp.10060.

Address correspondence to:
Roy K. Philip, FRCP, FRCPCH, FJFICMI, MD, MBA
Division of Neonatology
Department of Paediatrics
Graduate Entry Medical School (GEMS)
University of Limerick & University Maternity Hospital Limerick
Limerick V94 C566
Ireland
E-mail: roy.philip@hse.ie